Emerald Advisers’s Fate Therapeutics FATE Stock Holding History

Emerald Advisers’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-176,956	Closed	-$10.5M	–	285
2021 Q3	$10.5M	Buy	+176,956	New	+$13.9M	0.38%	96

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers's FATE Position: Q4 2021 in Review

Emerald Advisers sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 176,956 shares — an estimated $10.5M sold.

Emerald Advisers first reported a position in FATE in Q3 2021 and held it in 1 quarter. The position peaked at $10.5M in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

Emerald Advisers reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
Emerald Advisers sold 176,956 Fate Therapeutics shares in Q4 2021, an estimated $10.5M.
Emerald Advisers first reported a position in Fate Therapeutics in Q3 2021 and held it in 1 quarter.
Emerald Advisers's Fate Therapeutics position peaked at $10.5M in Q3 2021.
250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Emerald Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.